dc.contributor.author | Haybar, H | |
dc.contributor.author | Javid, AZ | |
dc.contributor.author | Haghighizadeh, MH | |
dc.contributor.author | Valizadeh, E | |
dc.contributor.author | Mohaghegh, SM | |
dc.contributor.author | Mohammadzadeh, A | |
dc.date.accessioned | 2018-08-26T09:40:09Z | |
dc.date.available | 2018-08-26T09:40:09Z | |
dc.date.issued | 2018 | |
dc.identifier.uri | http://dspace.tbzmed.ac.ir:8080/xmlui/handle/123456789/58364 | |
dc.description.abstract | Background: Despite advances in the treatment of cardiovascular diseases in recent decades, patients experience high levels of depression, anxiety, stress, and insomnia. Since the calming effect of Melissa officinalis (MO) has been known, this study aimed to determine the effects of MO supplementation on depression, anxiety, stress, and sleep disturbances in patients with chronic stable angina (CSA). Methods: In this double-blind placebo-controlled clinical trial, 80 patients with CSA were divided randomly into two groups (taking 3 g MO supplement or placebo daily for 8 weeks). The shortened 21-item version of the depression, anxiety and stress scale (DASS-21) test and Pittsburgh sleep quality index were done before and after the intervention. Results: At the end of the study, the intervention group receiving MO capsules had a significant reduction in scores of depression, anxiety, stress, and total sleep disturbance, compared with the placebo group (P < 0.05). Conclusions: The results showed that 8-week supplementation with 3 g MO can decrease depression, anxiety, stress, and sleep disorder in patients with CSA. © 2018 European Society for Clinical Nutrition and Metabolism | |
dc.language.iso | English | |
dc.relation.ispartof | Clinical Nutrition ESPEN | |
dc.subject | alpha tocopherol | |
dc.subject | ascorbic acid | |
dc.subject | beta carotene | |
dc.subject | cholesterol | |
dc.subject | herbaceous agent | |
dc.subject | Melissa officinalis supplemment | |
dc.subject | monounsaturated fatty acid | |
dc.subject | placebo | |
dc.subject | polyunsaturated fatty acid | |
dc.subject | protein | |
dc.subject | unclassified drug | |
dc.subject | adult | |
dc.subject | anxiety | |
dc.subject | Article | |
dc.subject | controlled study | |
dc.subject | daytime somnolence | |
dc.subject | depression | |
dc.subject | Depression Anxiety Stress Scale | |
dc.subject | double blind procedure | |
dc.subject | female | |
dc.subject | human | |
dc.subject | international physical activity questionnaire | |
dc.subject | major clinical study | |
dc.subject | Melissa officinalis | |
dc.subject | middle aged | |
dc.subject | Pittsburgh Sleep Quality Index | |
dc.subject | randomized controlled trial | |
dc.subject | sleep disorder | |
dc.subject | sleep efficiency | |
dc.subject | sleep latency | |
dc.subject | sleep parameters | |
dc.subject | sleep quality | |
dc.subject | sleep time | |
dc.subject | stable angina pectoris | |
dc.subject | stress | |
dc.title | The effects of Melissa officinalis supplementation on depression, anxiety, stress, and sleep disorder in patients with chronic stable angina | |
dc.type | Article | |
dc.citation.volume | 26 | |
dc.citation.spage | 47 | |
dc.citation.epage | 52 | |
dc.citation.index | Scopus | |
dc.identifier.DOI | https://doi.org/10.1016/j.clnesp.2018.04.015 | |